ST Pharm and Quantoom Partner to Enhance RNA Manufacturing Flexibility

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Quantum Computing Advances Make Way for Lifesaving Therapies

The fact is that there is something very profoundly...

ST Pharm and Quantoom Biosciences have announced an extended collaboration to advance the development and manufacturing of RNA-based vaccines and therapeutics. This partnership integrates the complementary strengths of both companies to enhance the global supply of critical RNA manufacturing technologies. A key component of the collaboration is the initial supply agreement for ST Pharm’s proprietary 5’-capping reagent, SmartCap®.

The collaboration is designed to leverage the advanced RNA technologies developed by both companies, providing a more robust and flexible RNA manufacturing ecosystem. ST Pharm, a CDMO specializing in RNA technology, will benefit from insights into Quantoom’s Ntensify mRNA production processes. In return, Quantoom will gain access to ST Pharm’s advanced IVT-based mRNA-LNP platform, including novel capping and formulation reagents.

The partnership is expected to accelerate the development of innovative RNA-based therapies by combining the expertise and resources of both companies. Mooje Sung, CEO of ST Pharm, commented, “This collaboration represents a significant step forward in our mission to provide cutting-edge and competitive RNA technologies to the global market.”

José Castillo, CEO of Quantoom Biosciences, also expressed enthusiasm about the partnership, stating, “By securing access to ST Pharm’s unique technologies, we are empowering our clients with unparalleled flexibility and control over their mRNA production processes.”

Latest stories

Related stories

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pharma Sector Reactions to US-EU Trade Framework Deal

The United States and the EU have, on August...

Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers

The Chinese pharmaceutical firms are increasingly looking out for...

Quantum Computing Advances Make Way for Lifesaving Therapies

The fact is that there is something very profoundly...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back